BACKGROUND AND OBJECTIVES: We compared the decline of RRF in patients starting dialysis on APD with those starting on CAPD, because a faster decline on APD has been suggested. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: NECOSAD patients starting dialysis on APD or CAPD with RRF at baseline were included and followed for 3 years. Residual GFR (rGFR) was the mean of urea and creatinine clearances. Differences in yearly decline of rGFR were estimated in analyses with linear repeated measures models, whereas the risk of complete loss of RRF was estimated by calculating hazard ratios (HRs) for APD compared with CAPD. As-treated (AT) and intention-to-treat (ITT) designs were used. All of the analyses were adjusted for age, gender, comorbidity, and primary kidney disease and stratified according to follow-up and mean baseline GFR. RESULTS: The 505 CAPD and 78 APD patients had no major baseline differences. No differences were found in the analyses on yearly decline of rGFR. APD patients did have a higher risk of losing RRF in the first year (ITT crude HR 2.43 [confidence interval 95%, 1.48 to 4.00], adjusted 2.66 [1.60 to 4.44]; AT crude 1.89 [1.04 to 3.45], adjusted 2.15 [1.16 to 3.98]). The higher risk of losing all RRF was most pronounced in patients with the highest rGFR at baseline (ITT; crude 3.91 [1.54 to 9.94], adjusted 1.85 to 14.17). CONCLUSIONS: The risk of losing RRF is higher for patients starting dialysis on APD compared with those starting on CAPD, especially in the first year.
BACKGROUND AND OBJECTIVES: We compared the decline of RRF in patients starting dialysis on APD with those starting on CAPD, because a faster decline on APD has been suggested. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: NECOSAD patients starting dialysis on APD or CAPD with RRF at baseline were included and followed for 3 years. Residual GFR (rGFR) was the mean of urea and creatinine clearances. Differences in yearly decline of rGFR were estimated in analyses with linear repeated measures models, whereas the risk of complete loss of RRF was estimated by calculating hazard ratios (HRs) for APD compared with CAPD. As-treated (AT) and intention-to-treat (ITT) designs were used. All of the analyses were adjusted for age, gender, comorbidity, and primary kidney disease and stratified according to follow-up and mean baseline GFR. RESULTS: The 505 CAPD and 78 APDpatients had no major baseline differences. No differences were found in the analyses on yearly decline of rGFR. APDpatients did have a higher risk of losing RRF in the first year (ITT crude HR 2.43 [confidence interval 95%, 1.48 to 4.00], adjusted 2.66 [1.60 to 4.44]; AT crude 1.89 [1.04 to 3.45], adjusted 2.15 [1.16 to 3.98]). The higher risk of losing all RRF was most pronounced in patients with the highest rGFR at baseline (ITT; crude 3.91 [1.54 to 9.94], adjusted 1.85 to 14.17). CONCLUSIONS: The risk of losing RRF is higher for patients starting dialysis on APD compared with those starting on CAPD, especially in the first year.
Authors: Constantin J Konings; Jeroen P Kooman; Ulrich Gladziwa; Frank M van der Sande; Karel M Leunissen Journal: Kidney Int Date: 2005-03 Impact factor: 10.612
Authors: Ana Rodríguez-Carmona; Miguel Pérez Fontán; Elvia García López; Teresa García Falcón; Helena Díaz Cambre Journal: Perit Dial Int Date: 2007 May-Jun Impact factor: 1.756
Authors: Simon J Davies; Elvia Garcia Lopez; Graham Woodrow; Kieron Donovan; Jorg Plum; Paul Williams; Ann Catherine Johansson; Hans-Peter Bosselmann; Olof Heimburger; Ole Simonsen; Andrew Davenport; Bengt Lindholm; Anders Tranaeus; Jose C Divino Filho Journal: Nephrol Dial Transplant Date: 2008-05-02 Impact factor: 5.992
Authors: Scott D Bieber; John Burkart; Thomas A Golper; Isaac Teitelbaum; Rajnish Mehrotra Journal: Am J Kidney Dis Date: 2014-01-11 Impact factor: 8.860
Authors: Il-Soo Ha; Hui K Yap; Reyner L Munarriz; Pedro H Zambrano; Joseph T Flynn; Ilmay Bilge; Maria Szczepanska; Wai-Ming Lai; Zenaida L Antonio; Ashima Gulati; Nakysa Hooman; Koen van Hoeck; Lina M S Higuita; Enrico Verrina; Günter Klaus; Michel Fischbach; Mohammed A Riyami; Emilja Sahpazova; Anja Sander; Bradley A Warady; Franz Schaefer Journal: Kidney Int Date: 2015-04-15 Impact factor: 10.612